
Angiogénesis
Subcategorías de "Angiogénesis"
- BTK(165 productos)
- Bcr-Abl(117 productos)
- EGFR(562 productos)
- FAK(72 productos)
- FLT(89 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(177 productos)
- JAK(245 productos)
- PDGFR(127 productos)
- RAAS(86 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(52 productos)
- VDA(2 productos)
- VEGFR(239 productos)
Se han encontrado 2242 productos de "Angiogénesis"
EGFR-IN-159
CAS:EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.
Fórmula:C21H23N3O5Forma y color:SolidPeso molecular:397.424JAK3 covalent inhibitor-1
CAS:JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFórmula:C22H17FN6O2SPureza:98%Forma y color:SolidPeso molecular:448.47Gamendazole
CAS:Gamendazole is a novel drug candidate for male contraception. It has been shown to reduce fertility in male rats without affecting testosterone levels.Fórmula:C18H11Cl2F3N2O2Pureza:98%Forma y color:SolidPeso molecular:415.19SORT1-IN-5
CAS:SORT1-IN-5 (compound 3) is a SORT1 inhibitor capable of crossing the blood-brain barrier. The MSOH salt form of SORT1-IN-5 exhibits a certain degree of oral bioavailability.Fórmula:C19H31NO6SForma y color:SolidPeso molecular:401.52JAK3-IN-7
CAS:JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction afterFórmula:C17H20N6OPureza:98.81%Forma y color:SolidPeso molecular:324.38Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Fórmula:C19H19F2N7O3Forma y color:SolidPeso molecular:431.40HG-7-86-01
CAS:HG-7-86-01 is a selective type II tyrosine kinase inhibitor with antiproliferative activity against mutant T315I- Bcr-Abl for chronic myeloid leukemia (CML).Fórmula:C28H21F3N6O2SPureza:99.07%Forma y color:SolidPeso molecular:562.57VEGFR-2-IN-17
VEGFR-2-IN-17 (15a) is a potent VEGFR-2 inhibitor with an IC50 of 67.25 nM, showing significant antitumor effects.Fórmula:C21H14ClN3O2Forma y color:SolidPeso molecular:375.81Tyk2-IN-20
CAS:Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.Fórmula:C24H25N7O2Forma y color:SolidPeso molecular:443.50EGFR-IN-149
CAS:EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.Fórmula:C16H15N3OSForma y color:SolidPeso molecular:297.375I194496
CAS:I194496 is an effective inhibitor of cystathionine γ-lyase (CSE) with an IC50 value of 0.79 mM. It inhibits the growth of human TNBC cells by dual targeting the PI3K/Akt and Ras/Raf/ERK pathways. Additionally, I194496 suppresses the metastasis of human TNBC cells by downregulating the Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways.Fórmula:C28H23F2N5O5SForma y color:SolidPeso molecular:579.58JAK1-IN-16
JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.Fórmula:C20H15ClF3N3OSForma y color:SolidPeso molecular:437.87Clifutinib
CAS:Clifutinib (Compound 9e) is an orally active, selective inhibitor of FMS-like tyrosine kinase 3 (FLT3-ITD) with an IC50 of 15.1 nM. It inhibits FLT3-ITD kinase activity and blocks downstream signaling pathways, including RAS/MAPK, PI3K/AKT, and JAK/STAT5. Clifutinib induces apoptosis in FLT3-ITD mutated acute myeloid leukemia (AML) cells and is a potential candidate for research in relapsed/refractory FLT3-ITD positive AML.
Fórmula:C29H34N4O4Forma y color:SolidPeso molecular:502.605WDR5-MYC-IN-2
CAS:WDR5-MYC-IN-2 is an inhibitor of the WDR5-MYC protein-protein interaction (PPI) with an IC50 of 0.59 μM. It is utilized in research on MYC-driven cancers and in the development of other potent WDR5-MYC PPI inhibitors.Fórmula:C22H20BrClN4O4SForma y color:SolidPeso molecular:551.84Londamocitinib
CAS:Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.Fórmula:C28H31F2N7O4SPureza:98.64% - 99.56%Forma y color:SolidPeso molecular:599.65Ref: TM-T11706
1mg170,00€5mg416,00€10mg567,00€25mg858,00€50mg1.108,00€100mg1.485,00€1mL*10mM (DMSO)537,00€YLIU-4-105-1
CAS:YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.Fórmula:C32H34F3N7O2Forma y color:SolidPeso molecular:605.65FGFR1 inhibitor-15
CAS:FGFR1inhibitor-15 (Compound 23) is an FGFR1 inhibitor with an IC50 value of 27 μM, useful for tumor research.Fórmula:C17H13FN4OForma y color:SolidPeso molecular:308.31JAK3-IN-11
CAS:JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.Fórmula:C23H23N5O2Forma y color:SolidPeso molecular:401.46HDAC-IN-35
HDAC-IN-35 (Compound 14) is an effective and selective inhibitor of VEGFR-2 and HDAC, with IC50 values of 13.2 and 0.166 μM for VEGFR-2 and HDAC6, respectively.Fórmula:C17H13ClF3N3O3Forma y color:SolidPeso molecular:399.75EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Forma y color:Solid

